In silico studies of novel synthetic compounds as potential drugs to inhibit coronavirus (SARS-CoV-2): A systematic review

5Citations
Citations of this article
28Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), detected first in China, spread out fast to other parts of the world, and was soon recognized as a pandemic in March 2020. According to WHO, 179.686.071 confirmed cases and 3.899.172 deaths due to new coronavirus were reported worldwide on 26th June 2021. Despite countless efforts in searching for repositioned drugs to treat this disease, the results are still modest. Thus, the search for new molecular entities in the treatment of COVID-19 is an essential field in medicinal chemistry. Since the pandemic's beginning, several studies have reported the synthesis of novel organic compounds and their in silico interactions with the new coronavirus. Such computational studies are currently being applied to unveil the complexities of drug-target molecule interaction and also helping in developing new pharmacological treatments. This systematic review aims to provide an overview of studies describing the utilization of novel compounds as prospective drugs in the treatment of COVID-19.

Author supplied keywords

Cite

CITATION STYLE

APA

Porto, V. A., & Porto, R. S. (2022, August 15). In silico studies of novel synthetic compounds as potential drugs to inhibit coronavirus (SARS-CoV-2): A systematic review. Biointerface Research in Applied Chemistry. AMG Transcend Association. https://doi.org/10.33263/BRIAC124.42934306

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free